The Top 3 Nuclear Energy Stocks to Buy Right Now

Oklo received DoE approval for the Nuclear Safety Design Agreement (NSDA) for its Idaho 'Aurora Powerhouse' 75 MW SMR and Atomic Alchemy obtained an NRC materials license; the Aurora is targeted to begin commercial operations by late 2027. NuScale signed an agreement with Ebara Elliott to field-test SMR-powered high-temperature steam compressors aiming to produce process heat at ~500°C+, potentially opening a large petrochemical steam market if successful. Duke Energy (~$100B market cap) provides a lower-risk exposure to nuclear with a 3.3% dividend yield and shares up ~10% YTD. Investors should note Oklo and NuScale remain early-stage, high-volatility companies with meaningful regulatory and operational risks.

Analysis

The recent regulatory movement accelerates an already high-conviction bifurcation: incumbents with stable cash flows and operating reactors will capture near-term investor returns, while SMR developers remain binary, calendar-driven bets. Expect meaningful dispersion in implied volatility across these names over the next 6–24 months as discrete NRC/DOE milestones and a small number of industrial pilot tests drive repricing; a single failed test or material delay can erase >50% of market cap in the most speculative tickers.

Second-order winners include suppliers of high-temperature steam balance-of-plant (turbomachinery, heat exchangers, specialty alloys) and radiopharma isotope processors — these address recurring revenue pools that improve unit economics for projects and shorten payback periods versus power-only sales. Conversely, US gas-fired peakers and merchant generators face chronic margin compression in regions that adopt SMR process-heat contracts, shifting capacity-value to firm low-carbon baseload and opening utility IRR upside for vertically integrated players with transmission access.

Tail risks cluster around financing, supply-chain bottlenecks, and regulatory precedents: expect 12–36 month rollback scenarios where capital markets tighten, insurance/product liability frameworks are unsettled, or NRC queries require design rework — any of which pushes commerciality timelines into multi-year erosion of optionality. For risk-managed exposure, prefer dividend-bearing utility exposure to capture nuclear upside via lower beta and pair speculative option positions that cap downside while preserving asymmetric upside from successful regulatory/technical catalysts.

Key Decisions for Investors

• Long DUK stock size: 3–5% portfolio, horizon 12–36 months. Rationale: buy stable utility cash flows and dividend (3.3% yield) to capture grid/nuclear tailwinds while avoiding startup execution risk. Hedge: sell DUK 9–12 month covered calls at ~15–20% OTM to enhance yield; target total return 8–12% if no big re-rating.
• Event-driven long on SMR (NuScale) via calendar call spread: buy 9–12 month ATM calls and sell 18–24 month higher-strike calls (debit spread) sized 0.5–1% portfolio. Risk/Reward: limited downside to premium paid, upside capped but >3x return if industrial steam test validates 500°C capability and secures multi-plant order pipeline within 6–12 months.
• Hedge/short protection vs OKLO: buy 12–18 month put spreads on OKLO (protective, capped-cost). Position sizing small (0.5–1% portfolio) to guard against >50% downside from regulatory rework or funding shortfall; if comfortable with long-biased spec exposure, replace some straight equity purchases with long-dated call options to limit cash at risk.
• Pair trade for asymmetric alpha: long DUK / short a basket of speculative SMR names (weighted OKLO:SMR = 60:40) via modest equity/option exposure over 12 months. Rationale: capture steady dividend + upside from grid firming while benefiting if speculative valuations compress after typical post-catalyst volatility; target 10–15% annualized outperformance with max drawdown capped by options.